Key Evidence About NGS-Based Personalized Cancer Immunotherapy
Current scientific data show several important realities:
- Only about 30% of patients respond to current immunotherapies overall.
- Com Next-Generation Sequencing (NGS), doctors can identify mutations and biomarkers that predict response and choose targeted therapy.
- In clinical studies:
- ~37% of patients have actionable genetic alterations detected by NGS.
- About 35% of patients may benefit directly from NGS-guided targeted therapy depending on cancer type and access to drugs.
- In some specific cancers, response rates with matched therapies may reach 80%, but only in selected patients with specific mutations.
2. Explanation
Personalized Cancer Treatment Using Next-Generation Sequencing (NGS)
Modern oncology increasingly uses a technology called Next-Generation Sequencing (NGS) to design highly personalized cancer treatments. This approach is part of what is known as precision medicine ou personalized immunotherapy.
What is Next-Generation Sequencing (NGS)?
NGS is a laboratory technology that allows doctors to analyze the genetic profile of a patient’s tumor in great detail.
Cancer develops because of mutations in DNA. Each patient’s tumor has a unique combination of these mutations. NGS can identify hundreds of genetic changes in a tumor from a small tissue sample or blood sample (liquid biopsy).
This genetic information helps doctors:
• identify mutations driving the cancer
• detect targets for specific drugs
• predict which therapies are most likely to work
• identify biomarkers for immunotherapy response
Em outras palavras, NGS allows treatment to be customized to the molecular biology of the patient’s tumor, rather than using the same therapy for all patients.
How NGS Helps Train the Immune System Against Cancer
The immune system can recognize cancer cells if it detects abnormal proteins called neoantigens. These neoantigens arise from tumor-specific mutations.
Using NGS, scientists can:
- Sequence the tumor genome
- Identify mutations unique to the tumor
- Predict which mutations create neoantigens
- Design therapies that stimulate immune cells to attack those targets
This approach is used in several strategies:
1. Immune checkpoint therapy selection
NGS helps identify biomarkers (for example tumor mutation burden or specific gene mutations) that predict response to immunotherapy.
2. Targeted therapies
Some mutations can be treated with drugs that specifically block the cancer-driving pathway.
3. Personalized cancer vaccines
Researchers can design vaccines based on the patient’s tumor mutations to stimulate a highly specific immune response against cancer cells.
How Effective Is This Approach?
Personalized medicine using NGS is promising, but it is important to understand realistic expectations.
Scientific studies show that:
• About 30% of cancer patients respond well to current immunotherapy treatments.
• NGS identifies actionable genetic targets in roughly 40% of patients.
• In real-world studies, em volta 35% of patients can receive a personalized therapy based on NGS results.
In some specific cancers where a strong targetable mutation is found, response rates to matched therapies may be significantly higher.
Can NGS Prevent Cancer?
it helps:
• choose the most effective treatment
• avoid ineffective therapies
• improve survival in selected patients
• identify hereditary cancer risks in some cases
No futuro, NGS-guided therapies and personalized cancer vaccines may play a role in earlier intervention and prevention of relapse, but this area is still under active research.
The Future of Personalized Immunotherapy
NGS is a key technology driving the next generation of cancer treatment. Researchers are currently developing:
• personalized neoantigen vaccines
• AI-guided drug selection
• combination immunotherapies
• individualized immune cell therapies
These approaches aim to transform cancer treatment from a one-size-fits-all approach to a fully personalized immune-based strategy.
✅ Summary
Next-Generation Sequencing allows doctors to analyze the genetic mutations in a patient’s tumor and design personalized treatment strategies. While this technology does not cure or prevent all cancers, it significantly improves the ability to select targeted therapies and immunotherapies, and it represents one of the most promising directions in modern oncology.
